Breaking News
November 16, 2018 - Researchers find no link between ‘allergy friendly’ dogs and lower risk of asthma
November 16, 2018 - Researchers elucidate new rules of connectivity of neurons in the neocortex
November 16, 2018 - Treating children with ‘bubble baby disease’
November 16, 2018 - AHA: PTSD Common Among Those Who Suffer Tear in the Aorta’s Wall
November 16, 2018 - Many RA patients’ pain related to central nervous system
November 16, 2018 - Changes in Himalayan gut microbiomes linked to diet
November 16, 2018 - Inhibition of prostaglandin E2 enhances ability to combat infectious colitis
November 16, 2018 - Chronic dry eye can slow reading rate and disrupt day to day tasks
November 16, 2018 - Researchers develop new drug molecule that inhibits inflammation
November 16, 2018 - Dementia symptoms peak in winter and spring, study finds
November 16, 2018 - Stanford tobacco researcher weighs in on JUUL
November 16, 2018 - Increasing omega-3 fatty acid intake during pregnancy reduces risk of premature birth, review finds
November 16, 2018 - Researchers find no link between infants waking up at night and later developmental problems
November 16, 2018 - Both parents and children agree about confidential medical services
November 16, 2018 - FDA warns against use of unapproved pain medications with implanted pumps
November 16, 2018 - Precision medicine-based approach to slow or reverse biologic drivers of Alzheimer’s disease
November 16, 2018 - Study provides new insight into norovirus outbreaks, may help guide efforts to develop vaccines
November 16, 2018 - Inexpensive, portable air purifier could help protect the heart from pollution
November 16, 2018 - New 15-minute scan could help diagnose brain damage in babies up to two years old
November 16, 2018 - Deep brain stimulation not effective for treating early Alzheimer’s
November 16, 2018 - Traditional chemotherapy superior to new alternative for oropharyngeal cancers | News Center
November 16, 2018 - What This Pond Protist Does With Its Genome Will Astound You
November 15, 2018 - Researchers develop tool that speeds up analysis and publication of biomedical data
November 15, 2018 - Scientists identify mechanism used by lung cancer cells to obtain glucose
November 15, 2018 - Abnormalities in development of the brain could be involved in onset of autism, finds new study
November 15, 2018 - Soy protein equally effective as animal protein in building muscle strength
November 15, 2018 - American Academy of Pediatrics, Nov. 2-6
November 15, 2018 - Dopamine drives early addiction to heroin
November 15, 2018 - Variance in gut microbiome in Himalayan populations linked to dietary lifestyle | News Center
November 15, 2018 - Reducing Cardiovascular Disease: The Amish Way
November 15, 2018 - King’s researchers launch charter to guide organizations to engage abuse survivors in research
November 15, 2018 - Enable Injections enters into development agreements with UCB and Apellis Pharmaceuticals
November 15, 2018 - TGen North collaborates with NARBHA Institute to advance human health
November 15, 2018 - Researchers discover molecular basis for therapeutic actions of an African folk medicine
November 15, 2018 - Human Cell Atlas study of early pregnancy shows how mother’s immune system is modified
November 15, 2018 - New guidelines for detecting and managing sarcopenia to be launched in the UK
November 15, 2018 - Researchers explore role of dietary composition on energy expenditure
November 15, 2018 - Elsevier launches Entellect™ Platform, unlocking value by creating AI-ready life sciences data
November 15, 2018 - Now that cannabis is legal in Canada, let’s use it to tackle the opioid crisis
November 15, 2018 - In the Spotlight: At the intersection of tech, health, and ethics
November 15, 2018 - Traditional Glaucoma Test Can Miss Severity of the Disease
November 15, 2018 - Researchers directly connect activities of genes with instinctive behavior in male cichlids
November 15, 2018 - Salk researchers report new methods to identify AD drug candidates with anti-aging properties
November 15, 2018 - St. Jude Hospital announces availability of largest collections of leukemia samples
November 15, 2018 - Attenua Announces First Patient Treated in Phase 2 Clinical Trial in Chronic Cough with Bradanicline
November 15, 2018 - Designing a novel cell-permeable peptide chimera to promote wound healing
November 15, 2018 - NEI investigators combine two imaging modalities to view the retina in unprecedented detail
November 15, 2018 - Determining how hearts develop to better understand congenital heart defects
November 15, 2018 - Maverick immune cells can act independently to identify and kill cancer cells, finds research
November 15, 2018 - Advanced AI and big data methods to tackle dementia
November 15, 2018 - Report reveals increase in pancreatic cancer death rates across Europe
November 15, 2018 - Luxia Scientific announces availability of its gut microbiome test in Luxembourg
November 15, 2018 - New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis
November 15, 2018 - New approach targets matrix surrounding neurons to protect neurons after stroke
November 15, 2018 - Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
November 15, 2018 - Heart failure patients shouldn’t stop meds even if condition improves: study
November 15, 2018 - Parents and carers of people with diabetes experience emotional or mental health problems
November 15, 2018 - RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders
November 15, 2018 - Breakthrough research could lead to a new wave of cancer-fighting antibodies
November 15, 2018 - Mylan and Biocon launch new insulin glargine biosimilar in the UK
November 15, 2018 - For wildfire safety, only particular masks guard against toxic particulate matter
November 15, 2018 - New study of tribe shows influence of Western diet and lifestyle on blood pressure
November 15, 2018 - Scientists harness power of natural killer cells to treat children with neuroblastoma
November 15, 2018 - Investigating foodborne disease outbreak in Bosnia and Herzegovina based on simulation game
November 15, 2018 - Recommendations Issued for Management of Bradycardia
November 15, 2018 - Benefit unclear due to a lack of suitable studies
November 15, 2018 - TAMEST recognizes UT Southwestern’s Ralph DeBerardinis for changing our understanding of cancer
November 15, 2018 - Researchers discover key factors behind intestinal inflammation in CVID patients
November 15, 2018 - CityU develops first microarrayed 3D neuronal culture platform
November 15, 2018 - Expert suggests ways to control uncomfortable vaginal symptoms in diabetic women
November 15, 2018 - New edition of Red Journal focuses on roles of imaging in radiation oncology
November 15, 2018 - Doctors Aren’t Promoting Breastfeeding’s Cancer-Protection Benefit
November 15, 2018 - Collection of demonstration projects highlights value of patient engagement in research
November 15, 2018 - Technique to ‘listen’ to a patient’s brain during tumour surgery
November 15, 2018 - Seven-year-old returns to life as a “normal, healthy child” following bone marrow transplant
November 15, 2018 - AMSBIO expands range of high quality FFPE cancer cell line controls
November 15, 2018 - Marijuana use by kidney donors has no effect on transplant outcomes
November 15, 2018 - Exploring NMR Spectroscopy Applications through Interesting Infographics
November 15, 2018 - Chapman University wins additional $2.9 million NIH grant to study Alzheimer’s disease
November 15, 2018 - Microgel powder reduces infection and promotes healing
Early intervention may be crucial to successful treatment of Friedreich’s ataxia

Early intervention may be crucial to successful treatment of Friedreich’s ataxia

image_pdfDownload PDFimage_print

New research published today in Disease Models & Mechanisms indicates that early intervention should be a key target in the development of new therapeutics for Friedreich’s ataxia, as current treatments may be administered too late to target the disease effectively.

Around 1 in 50,000 people across the world are affected by Friedreich’s ataxia, an autosomal recessive inherited disease that causes progressive damage to the nervous system. Friedreich’s is the most common recessive ataxia (a lack of muscle control in voluntary movement) and results from deficient expression of the small mitochondrial protein frataxin. Mitochondria are the energy centres of the cell, relying on electron transport through a chain of enzymes that contain iron-sulphur clusters to produce the energy required for cell metabolism. Frataxin plays a vital role in this process by ensuring proper formation of the iron-sulphur clusters within the enzymes. In cells with reduced levels of frataxin, abnormal iron-sulphur cluster formation leads to decreased energy production and an accumulation of iron that induces cell-damaging reactive oxygen species (ROS). Damage from excess ROS then causes the degeneration of nervous tissue in the spinal cord. Additionally, individuals with Friedreich’s ataxia experience frequent fatigue resulting from cell metabolism defects. The usual initial symptom of the disorder is gait ataxia, a difficulty with walking that usually manifests in children between the ages of 5 and 15 years, although onset may occur in adulthood. The ataxia worsens over time and most individuals will ultimately require a wheelchair and assistance with daily tasks. Friedreich’s ataxia is commonly accompanied by a range of heart defects, and is also associated with carbohydrate intolerance and diabetes.

Identifying early deficiencies

Previous studies into Friedreich’s ataxia have investigated the direct effect of frataxin deficiency on mitochondrial enzymes that contain iron-sulphur clusters, but with a focus on nerve cell mitochondrial defects once symptoms had already been detected and the disease diagnosed. More recently, the focus of research has shifted to the deficiencies in mitochondrial biogenesis and respiratory chain complexes that occur before any symptoms are evident. Dr David Lynch, lead author on the study published in Disease Models & Mechanisms, explains that furthering knowledge of the earliest stages of Friedreich’s ataxia is essential, as their data suggest that the progressive degeneration in mitochondrial biogenesis leading to clinical disease is very slow. Lynch suggests that treatments developed to date may have failed because they didn’t target the disease at an early enough stage, and that early intervention is likely to prove crucial to successful therapy.

The advantages of slow progress

For their investigations, the team from the Children’s Hospital of Philadelphia, Weill Cornell Medical College, Queen’s University Belfast and the University of Pennsylvania used a frataxin knock-in/knockout model mouse model that has been available for a number of years, but had previously been overlooked for Friedreich’s ataxia research as the neurological phenotype is modest and has a slow onset. Lynch and the team, however, reasoned that a model that mirrored the slowly progressive nature of the disease might be more valid than the rapidly progressive mouse models more commonly used. Using this frataxin knock-in/knockout model, the researchers found significantly reduced levels of the mitochondrial biosynthesis master generator protein PGC-1α and biosynthesis pathway proteins Nrf1 and Tfam in mutant mice, even at pre-symptomatic stages of development. They also found evidence of reduced numbers of mitochondria and early mitochondrial deficiency in the cerebellar cortex. These results not only suggest early mitochondrial biogenesis deficits as a pathogenic mechanism, but also as a potential biomarker and therapeutic target in individuals with Friedreich’s ataxia.

An impact beyond Friedreich’s ataxia

Mitochondrial biogenesis deficits are associated with a number of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington’s disease and stroke. This means that new discoveries relating to mitochondrial defects in the progression, pathology or treatment of any one of these diseases can potentially be broadly applied. Lynch says, “I think our results rationalise directed studies toward improving mitochondrial biogenesis as a long-term therapy in Friedreich’s ataxia, and that the goals of therapy must include not only correcting iron-sulphur enzymes but also other mitochondrial dysfunction. This is a target, not only in Friedreich’s ataxia, but also in Parkinson’s disease, so it is likely that collaborative drug development can move forward.”

Source:

Home

Tagged with:

About author

Related Articles